Agios Pharmaceuticals, Inc.
https://www.agios.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Agios Pharmaceuticals, Inc.
In Investing, Oncology Is Still King, But Other Indications Joining The Royal Court
Investing in oncology has diminished as more focus goes to clinical-stage firms, while investment in preclinical companies in areas like neurology has been heating up.
Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
Agios Reports Phase III Success With Oral Drug For Thalassemia
The company hopes to position mitapivat as an oral treatment for patients across the thalassemia spectrum. A Phase III trial in non-transfusion-dependent alpha- or beta-thalassemia was positive.
Hematologists Consider Where New Therapies Fit In Sickle Cell Treatment Paradigm
The first gene editing medicine and gene therapy for sickle cell disease were approved as the ASH meeting got under way, but novel oral drugs may be key to making treatment more accessible.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice